ICER to assess tardive dyskinesia drugs

The Institute for Clinical Effectiveness and Economic Review said it will review the comparative clinical effectiveness and value of tardive dyskinesia compounds in an upcoming report to be published late this year. ICER said it expects the report to include a review of Ingrezza valbenazine and Austedo deutetrabenazine. The institute said it was "likely" that the report also would include Xenazine tetrabenazine.

FDA approved Ingrezza from Neurocrine Biosciences Inc. (NASDAQ:NBIX) for tardive dyskinesia on April 11. Ingrezza is a selective inhibitor of vesicular monoamine transporter 2 (VMAT2; SLC18A2)...